Alcoholic liver disease (ALD) is a leading cause of liver cirrhosis, liver cancer, and related mortality. The endocannabinoid system contributes to the development of chronic liver diseases, where cannabinoid receptor 2 (CB2) has been shown to have a protecting role. Thus, here, we investigated how CB2 agonism by 4′-O-methylhonokiol (MHK), a biphenyl from Magnolia grandiflora, affects chronic alcohol-induced liver fibrosis and damage in mice. A combination of alcohol (10% vol/vol) and CCl4 (1 ml/kg) was applied to C57BL/6 mice for 5 weeks. MHK (5 mg/kg) was administered daily, and liver damage assessed by serum AST and ALT levels, histology, gene, and protein expression. Endocannabinoids (ECs) and related lipid derivatives were measured by liquid chromatography and mass spectrometry (LC-MS) in liver tissues. In vitro, MHK was studied in TGFβ1-activated hepatic stellate cells (HSC). MHK treatment alleviated hepatic fibrosis, paralleled by induced expression of matrix metalloproteinases (MMP)-2, -3, -9, and -13, and downregulation of CB1 mRNA. Necrotic lesions and hepatic inflammation were moderately improved, while IL-10 mRNA increased and IFNγ, Mcl-1, JNK1, and RIPK1 normalized by MHK. Hepatic anandamide (AEA) and related N-acetylethanolamines (NAEs) were elevated in MHK group, whereas fatty acid synthase and diacylglycerol O-acyltransferase 2 expression reduced. In vitro, MHK prevented HSC activation and induced apoptosis via induction of bak1 and bcl-2. To conclude, MHK revealed hepatoprotective effects during alcohol-induced liver damage through the induction of MMPs, AEA, and NAEs and prevention of HSC activation, indicating MHK as a potent therapeutic for liver fibrosis and ALD.
Introduction
Excess alcohol consumption is the most frequent cause of liver cirrhosis worldwide, and in 2010, alcoholic liver cirrhosis was Nasser Semmo and Felix Stickel share equal contribution Electronic supplementary material The online version of this article (doi:10.1007/s00109-017-1556-y) contains supplementary material, which is available to authorized users. responsible for 493,300 deaths (47.9% of all liver cirrhosis deaths), representing 0.9% of all deaths regardless of the cause [1] . Moreover, alcoholic cirrhosis is the second most common indication for liver transplantation, accounting for approximately 40% of all primary liver transplants in Europe and about 25% in the United States [2] . Despite this huge burden of disease, no effective pharmacological treatment for alcoholic liver disease (ALD) is approved, and drug interventions are primarily focused on achieving abstinence or risk reduction by decreasing alcohol consumption [3] . Hence, novel therapeutic targets are clearly needed to specifically treat established ALD.
Mounting evidence indicates that the endocannabinoid system (ECS) plays an important role in various liver diseases including viral hepatitis, non-alcoholic fatty liver disease (NAFLD), ALD, hepatic encephalopathy, and autoimmune hepatitis [4] . In particular, upregulation of cannabinoid receptors (CB) 1 and 2 in almost all cronic liver diseases, cirrhosis, and related disturbances were convincingly demonstrated, leading to the intriguing therapeutic concept of functional antagonism of these receptors in liver pathophysiology, with CB1 promoting and CB2 protecting from liver damage [5] [6] [7] . Thus, in CB1 −/− and CB2 −/− mice, deletion of CB1 improved hepatic fibrosis and steatosis induced by carbon tetrachloride or high-fat diet (HFD), whereas the lack of CB2 increased collagen deposition, liver fat, and inflammation [8, 9] . In experimental alcoholic models, the CB2 agonist JWH-133 showed protective effects, as reflected by improved hepatic fibrosis, steatosis, inflammation, and liver regeneration [10] [11] [12] . Similarly, another CB2 agonist HU-308 alleviated tissue injury and decreased inflammatory cell infiltration and apoptosis during ischemia reperfusion [12] . As a traditional medicine, Magnolia extracts have been used to treat gastrointestinal, anxiety, and allergic diseases in Asian countries for several centuries [13] [14] [15] . Honokiol, magnolol, and 4′-O-methylhonokiol (MHK) are considered the major bioactive constituents of Magnolia grandiflora L. Although the structural similarity, MHK is the only compound which showed significant bioactive properties on the ECS as a CB2 agonist and COX-2 substrate specific inhibitor [16, 17] . Recent studies revealed that magnolol and honokiol positively affect body fat accumulation and insulin resistance in HFD-fed mice [18, 19] , as well as improved fasting and plasma insulin levels in a type 2 diabetic model, alleviated hepatic oxidative damage, hyperglycemia, and hyperlipemia [20] [21] [22] . Also, honokiol was found to induce apoptotic death in activated rat HSCs suggesting an antifibrotic effect, while there was no such effect on hepatocytes [23] . Magnolia officinalis extracts showed beneficial effects on hepatic lipid accumulation, inflammation, oxidative stress, and apoptosis in an HFD-induced obese mouse model [24] [25] [26] . M. officinalis treatment of the rats on alcohol diet completely normalized serum liver enzymes, reversed steatosis, and completely inhibited the increased maturation of sterol regulatory element-binding protein-1c (SREBP1c) in the liver [27] . Thus, Magnolia extracts seem to be promising candidates for ALD therapy. Here, we studied the therapeutic potential of MHK, a pure bioactive component of M. grandiflora and M. virginiana, in a murine model of alcohol-induced liver damage and fibrosis.
Materials and methods

Materials
The procedure of isolation and purification of 4′-OMethylhonokiol is described in details by A. Chicca et al. in reference [17] .
Animals
Male C57BL/6 mice, 10 weeks of age (20-25 g) , were obtained from Charles River, Sulzfeld, Germany, and kept under a 12 h light-dark cycle with free access to the chow (Provimi Kliba AG, Kaiseraugst, Switzerland) and water ad libitum. Animal experiments and all experimental protocols were approved by the research animal ethics committee and by the local board on animal care and experimentation of Canton Bern and were performed according to international guidelines concerning the conduct of animal experimentation.
Cells
Human hepatic stellate cells (HSC; ScienCell Research Laboratories, Carlsbad, CA) were cultured in Dulbecco's modified Eagle's medium (DMEM), containing 10% FBS, 2 mM glutamine, 100 U/mL penicillin, and 100 U/mL streptomycin. Cells were maintained at 37°C in 5% CO 2 humidified atmosphere. Cells were seeded onto 12-well plates and after reaching semi-confluent state starved in serum-free medium for the next 24 h. Treatment with 1-10 μM MHK was performed for 6-24 h in a complete serum-free medium.
In vivo model of liver injury and treatment
Liver fibrosis was induced in male adult C57BL/6 mice by chronic administration of combination of 10% (v/v) alcohol (EtOH) in sweetened drinking water (5% sucrose) daily and CCl4 (1 mL/kg, 1:10 in corn oil), by intraperitoneal injections (i.p.), 2× weekly. This model replicates the Bmultiple hits^mod-el, where CCl4 is used as an additional trigger to enhance the effect of ethanol on fibrosis development [28] , lacking in other animal models, such as Lieber-deCarli, Tsukamoto-French or NIAAA [29, 30] . Therefore, individual control groups (ethanol alone, CCl4 alone) were not used. The adaptation to alcohol included gradual increase and application of EtOH in drinking water starting from the low dose 1% at day 1 to maximum dose 10% at day 7. Therafter, animals were divided into three groups:
(1) sham (sweetened drinking water) + vehicle (n = 4); (2) EtOH + CCl4 + vehicle (n = 8); and (3) EtOH + CCl4 + MHK 5 mg/kg/day (n = 6). MHK was given by i.p. daily, for 5 weeks. As the effects of MHK on untreated animals on normal chow diet have been tested in reference [19] , this control group was not included. At the end of the experiment (2 days after the last CCl4 injection), animals were sacrificed under isofluorane anesthesia by puncture of the right heart ventricle and exsanguination. Blood and liver tissue samples were either snap frozen or collected in formalin for further analyzes.
Standard serum parameters
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in the internal laboratory of University Hospital Zürich, Institute of Clinical Chemistry.
Liver histology, immunohistochemistry, and morphometry
Tissue samples were fixed in formalin and embedded in paraffin using routine histological procedures. Deparaffinized 4 μm liver sections were stained with hematoxylin and eosin (H&E), and Sirius Red, according to the standard protocols and manufacturer's recommendations. Alpha smooth muscle actine (ɑSMA) stain was performed using anti-ɑSMA rabbit polyclonal antibody (Abcam; 1:200, overnight, 4°C) and detection performed with DAB Peroxidase (HRP) Substrate Kit (Dako, Denmark).
Morphometric quantification of Sirius Red staining was performed using an ImageJ 1.47 t software system [31] , and the results are presented as an area count, analyzed from 5 fields per section (magnification 40×). Hepatic inflammation was evaluated semiquantitatively, based on the distribution of the inflammatory cells (1-4, single cells to multiple cells/ islands/mild semi-confluent; 5-7, mild (semi-) confluentmoderate confluent; 8-10 severe confluent). Hepatic necrosis was evaluated semiquantitatively, based on the following scoring system: 1-single necrotic cells; 2-semi-confluent (not connected bridges of necrotic cells between portal and/ or central areas); and 3-confluent (connected bridges of necrotic cells between portal and/or central areas). All histological analyses were performed in blinded fashion.
TaqMan PCR
Total RNA was isolated from 30 mg of liver tissue using the RNeasy kit (Qiagen, Basel, Switzerland), and cDNA was transcribed from 1 μg of RNA using M-MLV reverse transcriptase (Invitrogen, Basel, Switzerland) with a random hexanucleotide mix (Roche, Basel, Switzerland). Quantitative real-time PCR was carried out on an ABI 7700 sequence detector (Applied Biosystems, Rotkreuz, Switzerland). All TaqMan probe and primer sets were obtained as ready-to-use kits from Applied Biosystems (Rotkreuz, Switzerland). For normalization, the housekeeping gene GAPDH was amplified in a parallel reaction.
Western blot analysis
All devices, materials, and reagents for Western blotting were obtained from Thermo Fisher Scientific, Reinach, Switzerland, if not stated otherwise. Liver tissue protein extracts were prepared using T-PER® (Tissue Protein Extraction Reagent) containing Complete™ protease inhibitor cocktail, Sample Reducing Agent Bolt™ (10×), and LDS Sample Buffer Bolt™ (4×), according to manufacturer's recommendations. Ten microliters (20 μg) of lysates were applied to Bolt™ 4-12% or 12% Bis-Tris Plus gels transferred to iBlot™ 2 NC Regular Stacks using iBlot® 2 Dry Blotting System and stained with 0.5% Ponceau S to assure equal protein loading and transfer. Membranes were blocked and incubated with the primary antibody overnight at 4°C, incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (Supplementary Table 1) , and proteins detected using the WesternBright™ Sirius Western blotting detection kit (Advansta, CA, USA). For quantification analysis, all proteins of interest were normalized to GAPDH.
Viability assay
Cell viability was measured using Quick Cell Proliferation Assay Kit II (ab65475) (Abcam, Cambridge, UK), according to manufacturer's recommendations.
Quantification of ECs and related lipids with LC-MS/MS
ECs, N-acetylethanolamines, and arachidonic acid were measured in the liver by liquid chromatography tandem mass spectrometry (LC-MS), as described in Supporting Information.
Statistical analysis
Comparison was performed with the one-way ANOVA Kruskal-Wallis test or Mann-Whitney U test, and survival was quantified with Kaplan-Meier analysis using the Graph Pad statistics software (Graph Pad Software Inc., San Diego, CA, USA). Results are given as means ± SD and considered statistically significant with a p value <0.05.
Results
MHK improves hepatic fibrosis
Five weeks of EtOH/CCl4 administration caused approximately 30% mortality, whereas MHK administration improved animal survival (Fig. 1a) . Body, liver, and spleen weights remained mainly unchanged after EtOH/CCl4 and MHK administration (not shown).
Liver histology of fibrotic mice showed mild to moderate fibrosis with wide-spread proliferation of ɑSMA- Morphometric analysis of Sirius Red staining demonstrated less pronounced extracellular matrix deposition after MHK treatment (Fig. 1c) , as well as actin protein expression was similar to that in untreated healthy control mice (Fig. 1d) . Though no major changes were noticed for PCα1, αSMA, and TGFβ1 mRNA by MHK, MMP-2, -3, -9, and -13 were strongly upregulated (Fig. 1e) .
MHK exerts mild anti-inflammatory effects in the liver
Toxic injury in mice resulted in pronounced perilobular neutrophilic infiltration, aligning fibrotic septas and necrotic areas (Fig. 2a) . Semi-quantitative evaluation revealed a reduced infiltration of immune cells upon MHK treatment (Fig. 2b) , although at mRNA levels, no major changes were detected, except of dramatic restoration of IFNγ. TNFɑ mRNA was slighlty upregulated by MHK (not significant), along with anti-inflammatory IL-10 ( Fig. 2c) . 
MHK protects from hepatocyte injury
Administration of EtOH/CCl4 resulted in moderate hepatotoxic injury, as evidenced by single cell decay or confluent areas of necrotic lesions from portal to central veins, or portal to portal areas (Fig. 3a) . Semi-quantitative evaluation indicated that MHK might have a protective effect from toxic damage, but this did not reach statistical significance (Fig. 3a) . However, serum markers of liver damage ALT and AST were markedly elevated in fibrotic group, and MHK significantly improved AST levels almost by 50% (Fig. 3b) . Apoptosisregulating bax, bak, and bcl-xl proteins were not affected neither in alcohol controls, nor by MHK treatment; however, Mcl-1 and necrosis-regulating JNK1 were significantly reduced by MHK (Fig. 3c, d ). Necroptosis-related RIPK1 was significantly downregulated by EtOH/CCL4, whereas MHK normalized its expression back to normal levels (Fig. 3e) . RIPK3 had similar tendency but not statistically significant.
Alcohol-metabolizing and oxidative stress-producing enzymes CYP2E1, CYP4A14, and p47-phox were not affected by MHK (Fig. 3f) .
MHK treatment increased hepatic AEA and related acetylethanomalides
MHK treatment significantly increased by approximately three times the concentrations of anandamide (AEA) and Nacetlyethanolamines (NAEs), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and linolenoy lethanolamine (LEA) including arachidonic acid (Fig. 4a) . On the contrary, 2-AG levels were not affected by MHK (Fig. 4a) .
At the same time, MHK upregulated the expression of lipid processing PPARγ and PNPLA3 mRNA compared with CCl4/ EtOH treatment alone and inhibited FAS and DGAT2 protein synthesis (Fig. 4b, c) . No major impact on the expression of SREBP1, MBOAT7, and ALDH1A1 was detected (Fig. 4b, c) .
In parallel, the expression of CB1 and CB2 receptors and the major enzymes involved in AEA and 2-AG biosynthesis and degradation was evaluated. Interestingly, MHK abolished CB1 receptor overexpression, induced by CCl 4 /EtOH, whereas no effects were detected on CB2, FAAH, MAGL, NAPE-PLD, PTPN22, DAGLβ, and COX-2 mRNA expression (Fig. 4d) .
MHK reduced human HSC activation and induced apoptosis
In vitro, human HSC was stimulated by TGFβ1 at 10 ng/mL to induce profibrogenic phenotype, and when treated with MHK at 5-10 μM, significant downregulation of PCα1(I), TGFβ1, αSMA, PDGFRβ, TNC, and TIMP1 was observed after the treatment for 24 h with the highest concentration 10 μM (Fig. 5a) . At protein level, this was confirmed by HSC activation markers tenascin c and actin, which were reduced by MHK 10-and 2-fold, respectively (Fig. 5b) .
Cell viability was strikingly reduced by MHK at higher doses 10 and 20 μM from 25 to 85%, respectively (Fig. 6a) , paralleled by the 2-3-fold induction of bak1 and bcl2 mRNA at 10 μM MHK (Fig. 6b) .
Discussion
MHK is traditionally used in Chinese medicine for the therapy of depression and anxiety and was tested in experimental animal models of memory impairment or Alzheimer's disease [14, [32] [33] [34] . Although only a few studies investigated the effects of MHK in peripheral disorders, experimental data suggests a potential anti-tumor property of MHK in the treatment of oral squamous cell, prostate, and colon carcinoma [35] [36] [37] . Other studies reported anti-inflammatory and anti-osteoclastogenic effects for MHK [38] . Regarding liver diseases, only one study demonstrated that MHK may positively impact metabolic syndrome: obesity, insulin resistance, and non-alcoholic steatohepatitis in a mouse high-fat diet model [19] .
Considering the putative role of ECS in chronic liver diseases, we studied the effects of MHK in alcohol-induced liver damage in mice and showed that it significantly improves survival, ALT, and AST levels and alleviates liver fibrosis and damage via modulation of MMP-2, -3, and -13 and CB1 expression. The contribution of matrix metalloproteinases to fibrosis resolution is widely reported, and the particular antifibrotic role of MMP-2, -3, and -13 has been convincingly demonstrated [39] . In addition, actin protein levels were significantly lower in MHK group, compared to fibrosis control, reflecting reduced HSC and myofibroblast number and activity. MMP expression, activation, and thus, fibrolysis might be sufficient to shift the balance between fibrogenesis and fibrolyis towards fibrosis resolution. In vitro, MHK strikingly suppressed the expression of PCα1(I), actin, TGFβ1, TIMP1, tenascin, PDGFRβ, and induced HSC apoptosis, confirming the direct anti-fibrogenic efficacy of MHK on HSC and myofibroblasts, which possibly could be detected only at certain time points in vivo. The profibrogenic role of CB1 receptor has been repeatedly reported, showing that genetic deletion or pharmacological antagonism of CB1 improves hepatic fibrosis, inflammation, and liver fat accumulation in various experimental models [40] . On the contrary, CB2 activation exerts anti-inflammatory and anti-fibrotic effects in liver and other organs [8, 10, 41] . Interestingly, in our study, MHK did not affect the expression of CB2, but strongly abolished CCl4/ MHK effect on hepatic lipid metabolism. a AEA, 2-AG, OEA, PEA, LEA, and arachidonic acid (AA) levels in the liver (mean ± SD; ***p < 0.001, **p < 0.01, *p < 0.05). b PPARγ, SREBP1, PNPLA3, and MBOAT7 mRNA, measured by TaqMan PCR, normalized to GAPDH (mean ± SD; *p < 0.05, ns non-significant). c Western blot and corresponding quantification of the bands of enzymes involved in lipid synthesis FAS, DGAT-2, and ALDH1A1 using ImageJ software system (mean ± SD; *p < 0.05, ns non-significant). d ECS-related mRNA expression: cannabinoid receptors CB1 amd CB2, ECs degrading and metabolizing enzymes FAAH, MAGL, and COX-2, ECs synthesizing enzymes NAPE-PLD, PTPN22, and DAGLβ, measured by TaqMan PCR and normalized to GAPDH (mean ± SD; *p < 0.05, ns non-significant) EtOH-induced upregulation of CB1, thus potentially leading to the inactivation of one of the major pro-fibrogenic pathways within the ECS network.
Despite many studies providing evidence for a protective effect of MHK from neuroinflammation [13, 32, 34] , the effect of MHK treatment on hepatic necroinflammation was only mild. Mice treated with MHK had slightly less neutrophilic infiltration in the periportal and pericentral areas of the liver. There was a trend towards improved levels of IL-6, IFNγ and induced anti-inflammatory IL-10 mRNA by MHK, but these differences failed to reach statistical significance. Previous findings by others indicated that MHK may have an inhibitory effect on COX-2 [17, 42] , but again, this was not confirmed in the present model, compatible with our findings of a lack of a striking effect on hepatic inflammation.
Next, the expression of genes coding for proteins involved in apoptosis, necrosis, and necroptosis was evaluated. Although the necrotic lesions in the MHK group seem to be Actin and tenascin protein expression in HSC activated by 10 ng/mL TGFβ1, measured after 24 h by Western blot, analyzed by ImageJ, and normalized to GAPDH (mean ± SD; *p < 0.05, ns non significant) less striking, semiquantitative quantification did not reveal statistically significant difference with a control group. However, the levels of liver function enzymes AST and ALT were significantly improved in MHK group. In line with this observation, downregulation of necroptotic RIPK1 in alcoholtreated mice was restored by MHK. RIPK1 had been shown to have a protective role, as RIPK1−/− mice die at birth, and rip −/− fibroblasts and thymocytes are sensitive to TNFα-induced cell death, as well as hematopoietic RIPK1 deficiency triggers both apoptotic and necroptotic death [43] [44] [45] . This indicates that MHK either directly or indirectly stimulates RIPK1 signaling pathways pivotal for survival.
No effects of MHK were found in the expression of proapoptotic bak, bax, and bcl-xl proteins, whereas Mcl-1 and necrosis-mediating JNK1 were increased by EtOH/CCl4 administration and markedly decreased to normal levels by MHK. All together, these data point to a protective potential of MHK in alcohol-mediated hepatic injury via the regulation of RIPK1, Mcl-1, and JNK signaling pathways.
Reduction of oxidative damage by MHK in embryopathies induced by nicotine, as well as improved memory impairment by the same mechanism had been reported previously [33, 46, 47] , and might partially explain the improvement of alcoholinduced liver damage in our study, which is also mediated by oxidative stress and free radical formation from alcoholinduced cytochrome P450 2E1 (CYP2E1). However, the expression of CYP2E1, CYP4A14, and p47-phox was not affected by MHK, indicating that MHK either influences other downstream proteins or has a direct neutralizing effect on alcohol, CCl4, and related oxidative stress products.
The increase of AEA and NAEs in MHK group was observed, while 2-AG concentration was not affected. This difference seems to be associated with the distinct modulation of the expression of AEA and 2-AG degrading enzymes. MHK showed a clear trend towards lowering the expression of AEA degrading enzyme FAAH (although not being statistically significant), while 2-AG degrading enzyme MAGL was not changed. None of the AEA, NAEs, and 2-AG biosynthetic enzymes were modulated by MHK. This data suggest that the specific increase of AEA and NAEs levels over 2-AG may result, at least in part, from a reduced hydrolysis. AEA and NAEs are PPARs ligand and can potentially contribute to the MHK protective effect. In addition, reduced AEA hydrolysis limits the release of free arachidonic acid which is the main COX-2 substrate, thus ultimately leading to reduced formation of pro-inflammatory prostaglandins. To elucidate whether other lipid metabolism pathways are involved in AEA and NAE regulation, also keeping in mind potential pro-steatotic effects of CB2 activation, we measured the expression of genes coding for related enzymes and transcription factors pertinent for lipid turnover. PPARγ and PNPLA3 mRNA expression was restored or induced by MHK, whereas SREBP1 and MBOAT7 were not affected neither by EtOH/CCl4 nor by MHK. This suggests a preponderance of lipid hydrolysis over synthesis, as also reflected by downregulation of FAS and DGAT-2 by MHK treatment in our model. In line with this observation, MHK was identified as a PPARγ agonist [36, 48] , delivering an explanation for its potential anti-steatotic functions, possibly via the insulinsensitizing and lipid-lowering effects of PPARγ [19, 49] .
The relatively mild molecular effects of MHK in our model could be explained by the rapid degradation of MHK, as shown in vitro using rat liver microsomes by Lee and coworkers, who demonstrated a high systemic plasma clearance and large volume of distribution, with an oral dose of 10 mg/kg resulting in a peak plasma concentration of only 24.1 ± 3.3 ng/mL at 3 h and a low estimated bioavailability [50] .
Our study has some weaknesses related to the animal model used which produces only an incomplete pattern of ALD as encountered in humans. Rodents are notoriously resistant to the hepatotoxic effects of alcohol due to species-related differences, and rodents only develop fibrosis when exposed to alcohol in combination with another toxin (e.g., carbon tetrachloride, thioacetamide) or major dietary manipulations (e.g., choline/methionine deficiency) (31) . In particular, our model produces little steatohepatitis and lacks typical microscopic lesions such as Mallory-Denk bodies. However, our data demonstrate a protective effect of MHK on liver damage induced by alcohol, resulting in reduced mortality, alleviated fibrosis, and necroinflammation, possibly via direct antifibrotic effects and modulation of lipid metabolism (Scheme 1). Though we expect similar effects in other models of alcohol-induced liver damage, further studies are necessary to understand whether the protective effects of MHK depend mainly on one pharmacological property (e.g., CB2 activation) or are the consequence of polypharmacoloigcal actions in the ECS (e.g., CB2 activation, limiting CB1 expression, increasing AEA, and NAE levels).
